The Politics of Fentanyl
The 2024 US election is undoubtedly significant, and to grasp its implications, it is crucial to delve into fentanyl and ...
Another Year, More Overdose Records
The latest data from the CDC has revealed that drug overdoses in the United States have reached another grim milestone ...
How to Recognize Toxic Stress
COVID-19 taught most people that the line between tolerable and toxic stress – defined as persistent demands – varies widely.
Public Health Experts Unable to Stop Gun Violence
Gun violence has exploded across the U.S. in recent years — from mass shootings at concerts and supermarkets to school ...
Is the Rise in ADHD Real?
Attention-Deficit/Hyperactivity Disorder (ADHD) has become a prevalent and concerning issue in our society, especially among children.
How Reporters Caught Payers Using Algorithms
Reporters share reporting tips which revealed how health insurance companies used a flawed computer algorithms.
Self-Medicating a Chronic Illness
With doctors hesitant to prescribe pain medication, many find themselves in a difficult position, forced to seek relief through other ...
Doctors Hate Working for You
With more doctors becoming employees of hospital systems, physician engagement is an issue, and it concerns lots of people in ...
Nudges Never Worked in Medicine
Nudges are often hailed as an effective tool in the field of behavioral economics, offering a gentle push towards desired ...
ProPublica Creates a Tool to Hold Payers Accountable
You have a right to know why a health insurer denies you. Yet some still won't tell you. We're aiming ...
A Small Measure of Justice
The United States Bureau of Prisons has gained control over more incarcerated American citizens than any other prison or jail ...
Fighting for Justice for Dr. Bockoff and His Patients
We are seeking justice for doctors to use their skills and justice for pain patients who desperately need relief from ...
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more